Daclatasvir

Daclatasvir is primarily used for treating chronic hepatitis C infections, often in combination with other antiviral medications such as sofosbuvir or ribavirin. Its effectiveness spans across various HCV genotypes, making it a valuable component in hepatitis treatment regimens. Emerging research indicates potential applications in treating other viral diseases, including COVID-19, by targeting early replication events and reducing inflammatory responses.

Daclatasvir exhibits potent antiviral activity against all HCV genotypes. Its mechanism involves disrupting both cis- and trans-acting functions of NS5A, leading to downregulation of hyperphosphorylation associated with HCV replication complexes. Clinical studies have shown that daclatasvir can significantly reduce serum HCV RNA levels and improve treatment outcomes when used in combination with other antiviral agents. Additionally, recent research suggests potential applications in treating other viral infections, including SARS-CoV-2, due to its ability to modulate inflammatory responses.

Please email your required order quantity and detailed technical specifications to sales@.
Our sales team will promptly prepare an accurate quotation for your bulk order and provide a comprehensive pricing proposal.

All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.